u/SecondPrevious7385 · 35d ago1 prior · awaiting results
$MAIA: An $80M Phase 3 oncology company with 17.8-month survival data, heavy insider buying, and partnerships with Regeneron, Roche and BeOne
MAIA is a small-cap oncology company with a Phase 3 trial underway for ateganosine, a first-in-class telomere-targeting immunotherapy showing 17.8-month median survival in Phase 2 (vs. 5-6 months historical chemotherapy). At $80M market cap with partnerships from Regeneron, Roche, and BeOne, success in the randomized Phase 3 trial could drive substantial revaluation in a large, underserved third-line NSCLC market.
At post $1.31Now $1.18-9.9% since postedas of Oct 12, 4:30 PM ET
1d+1.5%
3d-0.8%
1w+2.3%
1m-12.2%
3m—
6m—
1y—